Back to Search Start Over

Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group

Authors :
Enrico Papini
Claudio Maurizio Pacella
Luigi Alessandro Solbiati
Gaetano Achille
Daniele Barbaro
Stella Bernardi
Vito Cantisani
Roberto Cesareo
Arturo Chiti
Luca Cozzaglio
Anna Crescenzi
Francesco De Cobelli
Maurilio Deandrea
Laura Fugazzola
Giovanni Gambelunghe
Roberto Garberoglio
Gioacchino Giugliano
Livio Luzi
Roberto Negro
Luca Persani
Bruno Raggiunti
Francesco Sardanelli
Ettore Seregni
Martina Sollini
Stefano Spiezia
Fulvio Stacul
Dominique Van Doorne
Luca Maria Sconfienza
Giovanni Mauri
Source :
International Journal of Hyperthermia, Vol 36, Iss 1, Pp 375-381 (2019)
Publication Year :
2019
Publisher :
Taylor & Francis Group, 2019.

Abstract

Benign thyroid nodules are a common clinical occurrence and usually do not require treatment unless symptomatic. During the last years, ultrasound-guided minimally invasive treatments (MIT) gained an increasing role in the management of nodules causing local symptoms. In February 2018, the Italian MIT Thyroid Group was founded to create a permanent cooperation between Italian and international physicians dedicated to clinical research and assistance on MIT for thyroid nodules. The group drafted this list of statements based on literature review and consensus opinion of interdisciplinary experts to facilitate the diffusion and the appropriate use of MIT of thyroid nodules in clinical practice. (#1) Predominantly cystic/cystic symptomatic nodules should first undergo US-guided aspiration; ethanol injection should be performed if relapsing (level of evidence [LoE]: ethanol is superior to simple aspiration = 2); (#2) In symptomatic cystic nodules, thermal ablation is an option when symptoms persist after ethanol ablation (LoE = 4); (#3) Double cytological benignity confirmation is needed before thermal ablation (LoE = 2); (#4) Single cytological sample is adequate in ultrasound low risk (EU-TIRADS ≤3) and in autonomously functioning nodules (LoE = 2); (#5) Thermal ablation may be proposed as first-line treatment for solid, symptomatic, nonfunctioning, benign nodules (LoE = 2); (#6) Thermal ablation may be used for dominant lesions in nonfunctioning multinodular goiter in patients refusing/not eligible for surgery (LoE = 5); (#7) Clinical and ultrasound follow-up is appropriate after thermal ablation (LoE = 2); (#8) Nodule re-treatment can be considered when symptoms relapse or partially resolve (LoE = 2); (#9) In case of nodule regrowth, a new cytological assessment is suggested before second ablation (LoE = 5); (#10) Thermal ablation is an option for autonomously functioning nodules in patients refusing/not eligible for radioiodine or surgery (LoE = 2); (#11) Small autonomously functioning nodules can be treated with thermal ablation when thyroid tissue sparing is a priority and ≥80% nodule volume ablation is expected (LoE = 3).

Details

Language :
English
ISSN :
02656736 and 14645157
Volume :
36
Issue :
1
Database :
Directory of Open Access Journals
Journal :
International Journal of Hyperthermia
Publication Type :
Academic Journal
Accession number :
edsdoj.30c405aecfca474cbfc6e72bedda99a6
Document Type :
article
Full Text :
https://doi.org/10.1080/02656736.2019.1575482